Clinical Trials Logo

Clinical Trial Summary

Large-artery stenosis plays an important role in the occurrence of ischemic stroke. The primary purpose of this study is to evaluate the efficacy and safety of intensive antiplatelet therapy versus standard antiplatelet therapy and immediate high-intensity statin therapy (80mg atorvastatin) versus delayed high-intensity statin therapy (40mg atorvastatin) and intensive antiplatelet combined with immediate high-intensity statin therapy (80mg atorvastatin) versus standard antiplatelet combined with delayed high-intensity statin therapy (40mg atorvastatin) in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic extracranial or intracranial arterial stenosis.


Clinical Trial Description

Large-artery atherosclerotic stenosis is the main cause of ischemic stroke, especially in Asian population. However, targeted treatment evidence for large-artery atherosclerotic stenosis is limited according to the current guidelines. And also, randomized trial for statin therapy in patients with acute large arterial stenosis at early stage is still limited. The primary purpose of this study is to evaluate the efficacy and safety of intensive antiplatelet therapy versus standard antiplatelet therapy in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic extracranial or intracranial arterial stenosis; the efficacy and safety of immediate high-intensity statin therapy (80mg atorvastatin) versus delayed high-intensity statin therapy (40mg atorvastatin) in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic extracranial or intracranial arterial stenosis; and the efficacy and safety of intensive antiplatelet combined with immediate high-intensity statin therapy (80mg atorvastatin) versus standard antiplatelet combined with delayed high-intensity statin therapy (40mg atorvastatin) in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic extracranial or intracranial arterial stenosis. This trial is a randomized, double-blind, placebo-controlled, multicenter, 2×2 factorial designed clinical trial. 6100 patients in 250 centers in China will be enrolled with one of the following situations (1) Mild ischemic stroke (NIHSS 4~5) within 24 hours of onset meets any of the following imaging conditions: a) Acute single cerebral infarction with criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%),b) Acute multiple cerebral infarction (considered to be caused by large artery atherosclerosis, including non-stenotic vulnerable plaque);Or (2) Moderate-to-high-risk TIA (ABCD2≥4) or mild ischemic stroke (NIHSS≤5) within 24 to 72 hours of onset meets any of the following imaging conditions: a) Medium and high risk TIA with criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%),b) Acute single cerebral infarction with criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%),c) Acute multiple cerebral infarction (considered to be caused by large artery atherosclerosis, including non-stenotic vulnerable plaque) . Patients will be randomly assigned into 4 groups according to the ratio of 1:1:1:1: 1. Intensive antiplatelet therapy + immediate high-intensity statin therapy (80mg atorvastatin) 2. Intensive antiplatelet therapy + delayed high-intensity statin therapy (40mg atorvastatin) 3. Standard antiplatelet therapy + immediate high-intensity statin therapy (80mg atorvastatin) 4. Standard antiplatelet therapy + delayed high-intensity statin therapy (40mg atorvastatin) Face to face interviews will be made at baseline, 7, 14 (or hospital discharge), 90 ± 7 days and 12th month ± 14 days after randomization. Survival curves will be estimated for the primary outcome using the Kaplan-Meier procedure and compared using a Cox regression model Wald test, stratified by the opposite arm of the factorial design. Safety outcomes will be calculated using the Kaplan-Meier curve to simulate the 3-month cumulative risk, and the Cox proportional hazards model to calculate the HR and 95% confidence interval. Primary outcome is defined as stroke (including hemorrhagic and ischemic stroke). Secondary outcomes include composite vascular events (stroke, myocardial infarction, and cardiovascular death); ischemic stroke; transient ischemic attack; myocardial infarction; vascular death; all-cause death; poor functional outcome (mRS 2-6); and quality of life (EQ-5D scale). Safety outcomes, relating to antiplatelet therapy (i.e. bleeding, intracranial hemorrhage, and adverse events) and statin therapy (i.e. hepatotoxicity, muscle toxicity and adverse events) will be investigated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03635749
Study type Interventional
Source Beijing Tiantan Hospital
Contact
Status Active, not recruiting
Phase Phase 3
Start date September 17, 2018
Completion date October 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Enrolling by invitation NCT06074081 - Comparison of 4-weeks of Motor Relearning Program and Mirror Therapy in Improving Upper Limb Motor Function in Stroke Patients. N/A
Terminated NCT04039178 - Efficacy of EMF BCI Based Device on Acute Stroke N/A
Completed NCT04521634 - Glycaemic Variability in Acute Stroke
Completed NCT03477188 - The Effects of Somatosensory and Vestibular Rehabilitation Additional Conventional Therapy on Balance in Patients With Acute Stroke. N/A
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT02677415 - Impact of Anesthesia Type on Outcome in Patients With Acute Ischemic Stroke (AIS) Undergoing Endovascular Treatment N/A
Recruiting NCT01541163 - Heart and Ischemic STrOke Relationship studY N/A
Completed NCT01210729 - Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke Phase 2
Recruiting NCT00785343 - Study of Robot-assisted Arm Therapy for Acute Stroke Patients Phase 1
Completed NCT04779710 - How Does Dysphagia Assessment in Acute Stroke Affect Pneumonia?
Recruiting NCT06149754 - BraiN20® Monitoring in Acute Stroke Undergoing Thrombectomy
Recruiting NCT04491695 - Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke Phase 2/Phase 3
Recruiting NCT04283760 - Investigation of the Reliability and Validity of the Movement Imagination Questionnaire - Revised Second in Acute Stroke Patients
Recruiting NCT05454397 - A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients
Completed NCT04488692 - Early Functional Training in Acute Stroke Inpatient Ward N/A
Recruiting NCT04214522 - Reliability and Validity of the Kinesthetic and Visual Imagery Questionnaire in Acute Stroke Patients
Not yet recruiting NCT04157231 - Essential Acute Stroke Care in Low Resource Settings: a Pilot studY N/A
Recruiting NCT05469438 - IMAS Optimization and Applicability in an Acute Stroke Setting.
Completed NCT04734548 - Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke Phase 1/Phase 2